View the latest news and SEC filings
Scroll to
Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD population LONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces four oral presentations and
One oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces one oral presentation
Ohtuvayre TM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona
LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the 44 th Annual Canaccord Growth Conference on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m.
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
August 12, 2024 |
Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing |
144 |
Other |
|
|
August 9, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
August 9, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
August 9, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
August 8, 2024 |
Quarterly report which provides a continuing view of a company’s financial position |
10-Q |
Quarterly Filings |
|
|
August 8, 2024 |
Report of unscheduled material events or corporate event |
8-K |
Current Reports |
|
|
August 5, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
August 5, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
|
|
August 5, 2024 |
Statement of changes in beneficial ownership of securities |
4 |
3,4,5 |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
